The cancer survival rate can be prolonged, and the progress and development of cancer in preclinical tumor models can be delayed by combining RT with anti‐CTLA‐4,15 anti‐PD‐1,16 or anti‐PD‐L1 therapy methods.17, 18. The gene discussed is CTLA4; the disease is cancer.